In this paper relevant studies are summarized regarding the use of aca
rbose as an adjunct to insulin in the treatment of type I diabetes. It
is concluded that this approach may contribute to a reduction of post
prandial blood glucose excursions and a smoothening of daily blood glu
cose profiles, an improvement of metabolic control as expressed by gly
cosylate haemoglobin values and a reduction of insulin requirements. L
ong-term studies are, however, necessary before one can conclude that
addition of acarbose to the therapeutic regimen in type I diabetic sub
jects is of longstanding value.